152302-45-9

Basic information

• Product Name: 7-DesMethylagoMelatine
• Synonyms: 7-DesMethylagoMelatine;N-[2-(7-Hydroxy-1-naphthyl)ethyl]acetaMide;N-(2-(7-Hydroxynaphthalen-1-yl)ethyl)acetaMide;Agomelatine Impurity 14 Hydrochloride;Agomelatine Impurity 3;Agomelatine Impurity 7;Agomelatine Impurity 11;Agomelatine Impurity 10
• CAS NO: 152302-45-9
• Molecular Formula: C₁₄H₁₅NO₂
• Molecular Weight: 229.2744
• Mol File: 152302-45-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 511.3±33.0 °C(Predicted)
• Appearance: /
• Density: 1.183±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 9.68±0.40(Predicted)
• CAS DataBase Reference: 7-DesMethylagoMelatine(CAS DataBase Reference)
• NIST Chemistry Reference: 7-DesMethylagoMelatine(152302-45-9)
• EPA Substance Registry System: 7-DesMethylagoMelatine(152302-45-9)

Safety Data

• Hazardous Substances Data: 152302-45-9(Hazardous Substances Data)

Usage

General Description

7-DesMethylagoMelatine is a chemical compound derived from the natural hormone melatonin, and it is structurally related to agomelatine. It is a metabolite of agomelatine, and it has been found to be a potent agonist at melatonin receptors. 7-DesMethylagoMelatine has been studied for its potential use in the treatment of mood disorders, such as depression and anxiety. It has also shown promise in the regulation of circadian rhythms and sleep patterns. Additionally, 7-DesMethylagoMelatine may have antioxidative and neuroprotective properties, making it a potential candidate for further research and development in the field of neuropharmacology.

Upstream product

• 138112-76-2 agomelatine 
• 22009-38-7 7-hydroxy-1-tetralone 

Downstream Products

• 296280-56-3 N-(2-{7-[3-({8-[2-(acetylamino)ethyl]-2-naphthyl}oxy)propoxy]-1-naphthyl}-ethyl)acetamide 
• 250133-76-7 N-[2-(7-benzylsulfanyl-naphth-1-yl)ethyl]acetamide 
• 1095994-96-9 N-(2-{7-[(4-methoxybenzyl)amino]naphth-1-yl}ethyl)acetamide hydrochloride 
• 1096252-78-6 N-(2-{7-[(4-methoxybenzyl)amino]naphth-1-yl}ethyl)acetamide 
• 138112-76-2 agomelatine 

Relevant articles and documents

Evaluation of agomelatine stability under different stress conditions using an HPLC method with fluorescence detection: application to the analysis of tablets and human plasma

A simple and highly sensitive stability-indicating HPLC method was developed and validated for the determination of the new antidepressant agent, agomelatine (AGM). Separation of AGM from its stress-induced degradation products was achieved on a BDS Hypersil phenyl column (250 mm × 4.6 mm i.d., 5 μm particle size) using methanol–0.05 M phosphate buffer of pH 2.5 (35: 65, v/v) as a mobile phase with fluorescence detection at 230/370 nm. Naproxen was used as an internal standard. The method satisfied all the validation requirements, as evidenced by good linearity (correlation coefficient of 0.9999, over the concentration range 0.4–40.0 ng/mL), accuracy (recovery average 99.55 ± 0.90%), precision (intra-day RSD 0.54–1.35% and inter-day RSD 0.93–1.26%), robustness and specificity. The stability of AGM was investigated under different ICH recommended stress conditions including acidic, alkaline, neutral, oxidative and photolytic. AGM was found to be labile to acidic and alkaline degradation and a kinetic study was conducted to explore its degradation behavior. First-order degradation rate constants and half-life times were calculated in each case. The proposed method was applied for the determination of AGM in tablets and spiked human plasma with mean percentage recoveries of 99.87 ± 0.31 (n = 3) and 102.09 ± 5.01 (n = 5), respectively. Hence, the proposed method was successfully applied for the determination of AGM in human volunteer plasma. The results were compared statistically with those obtained by a comparison HPLC method revealing no significant differences between the two methods regarding accuracy and precision. Copyright

Substituted dimeric compounds

The invention relates to compound of formula (I): A—G1—Cy—G2—Cy′—G3—B??(I) wherein: A represents a grouping NR1C(Q)R2, C(Q)NR2R3or NR1C(Q)NR2R3, B represents a grouping NR1C(Q)R2, NR1C(Q)NR2R3, C(Q)NR2R3, C(Q)OR1, NR1C(Q)OR2or NR2R3, G1and G3represent an optionally substituted alkylene chain, Cy and Cy′, which are different, represent a ring structure or G2represents a chain and medicinal products containing the same are useful in treating or in preventing melatoninergic disorders.